sur Tharimmune, Inc.
Tharimmune announces positive Phase 1 results for TH104 and funding until 2025
Tharimmune, Inc., a clinical-stage biotechnology company, has completed its Phase 1 clinical trial with TH104, targeting inflammatory pruritic and hepatic conditions. TH104, a transmucosal buccal film containing nalmefene, has shown a tolerability profile comparable to its approved intravenous reference, according to preliminary results. The study involved 20 healthy volunteers, with 19 completing the protocol. Reported side effects were mild and self-resolving, consistent with prior studies and literature on nalmefene.
Tharimmune's next goal is to initiate a Phase 2 study for moderate to severe chronic pruritus in primary biliary cholangitis (PBC) in 2024. PBC, a chronic autoimmune cholestatic liver disease, causes "unbearable itch" and fatigue severely impacting quality of life, with a pressing need for effective solutions.
Having completed a public offering of $11 million last quarter, Tharimmune states it is financially secure until early 2025 for its clinical programs' outcomes, including TH104. The company also plans an R&D day in the second quarter of 2024 to provide updates to stakeholders.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Tharimmune, Inc.